American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Blood

Volumn 116, Issue 20, 2010, Pages 4045-4059

  Rizzo, J Douglas ^a   Brouwers, Melissa ^b   Hurley, Patricia ^c   Seidenfeld, Jerome ^c   Arcasoy, Murat O ^d   Spivak, Jerry L ^e   Bennett, Charles L ^f   Bohlius, Julia ^g   Evanchuk, Darren ^h   Goode, Matthew J ⁱ   Jakubowski, Ann A ^j   Regan, David H ^k   Somerfield, Mark R ^c   Schwartz, Carol ^l  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of South Carolina   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h Commonwealth Hematology Oncology PC ^*  (United States)

ⁱ Patient Representative   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Northwest Cancer Specialists   (United States)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; CONSENSUS DEVELOPMENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG USE; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEMATOLOGY; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 78549286047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-300541     Document Type: Review

References (76)

1. Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 3:CD003407, 2004
2. Engert A. Recombinant human erythropoietin in oncology: Current status and further developments. Ann Oncol. 2005;16:1584-1595. (Pubitemid 41510131)
3. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083-4107.
4. Seidenfeld J, Aronson N, Piper M, et al. Uses of epoetin for anemia in oncology. Evid Rep Technol Assess (Summ). 2001;29:1-8.
5. Seidenfeld J, Piper M, Aronson N. Systematic review of controlled trials on erythropoietin to support evidence-based guidelines. Oncology. (Williston Park) 2002(suppl 10);6:171-188.
6. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214. (Pubitemid 32816195)
7. Waltzman RJ. Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms. Semin Hematol. 2004;4:9-16.
8. Bennett CL, Henke M, Lai SY. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia (Reply). JAMA. 2008;300:2855-2857.
9. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
10. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407, 2006
11. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714.
12. Glaspy J, Smith R, Aapro M, et al. Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Presented at the 98th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 14-28, 2007
13. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394-403.
14. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260. (Pubitemid 37324251)
15. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960-5972.
16. Overgaard J, Hoff C, San Hansen H. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10. Eur J Cancer. 2007;7(suppl 5): Abstract 6LB.
17. Quirt I, Bramwell V, Charette M, et al. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. http://www.cancercare.on.ca/pdf/ pebc12-1f.pdf
18. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.
19. Seidenfeld J, Piper M, Bohlius J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: Comparative Effectiveness Review No. 3. http://effectivehealthcare. ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=display product&productid=35
20. Shehata N, Walker I, Meyer R, et al. Treatment for anemia with erythropoietic agents in patients with non-myeloid hematological malignancies: A Clinical Practice Guideline. http://www.cancercare.on.ca/pdf/pebc6-12s.pdf
21. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-202, iii-iv.
22. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032.
23. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108:317-325.
24. US Food and Drug Administration. FDA news release: FDA receives new data on risks of anemia drugs consistent with previous data on tumor growth and death. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116830. htm
25. US Food and Drug Administration. FDA briefing document, May 10, 2007, Oncologic Drugs Advisory Committee - Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/ 07/briefing/2007-4301b2-02-FDA.pdf
26. US Food and Drug Administration. FDA drug safety communication: Erythropoiesis-stimulating agents (ESAs): Procrit, Epogen and Aranesp. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm200297.htm
27. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer: Meta-analysis based on individual patient data. Cochrane Database Syst Rev 3:CD007303, 2009
28. Lambin P, Ramaekers BL, van Mastrigt GA, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 3:CD006158, 2009
29. Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008;42:1865-1870.
30. Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: A systematic review and meta-analysis. Oncologist. 2007;12:1264-1273. (Pubitemid 350106357)
31. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis. CMAJ. 2009;180:E62-E71.
32. Shehata N, Walker I, Meyer R, et al. The use of erythropoiesis- stimulating agents in patients with non-myeloid hematological malignancies: A systematic review. Ann Hematol. 2008;87:961-973.
33. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301-315.
34. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
35. Christodoulou C, Dafni U, Aravantinos G, et al. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Anticancer Res. 2009;29:693-702.
36. Hernandez E, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin. 2009;25:2109-2120.
37. Hoskin PJ, Robinson M, Slevin N, et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol. 2009;27:5751-5756.
38. Rearden TP, Charu V, Saidman B, et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J Clin Oncol. 2004;22(suppl): Abstract 8064, 745s.
39. Charu V, Saidman B, Ben-Jacob A, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007;12:1253-1263.
40. Aapro M, Barnadas A, Leonard RC, et al. What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta? Eur J Cancer. 2009;45:2984-2991.
41. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611-1618.
42. Glaspy JA, Charu V, Luo D, et al. Initiation of epoetin- alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: An open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009;115:1121-1131.
43. Gupta S, Singh PK, Bisth SS, et al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy." Cancer Biol Ther. 2009;8:13-17.
44. Heras P, Kritikos K, Hatzopoulos A, et al. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: A randomized, double-blind, dose-finding study. Eur J Cancer Care (Engl). 2008;17:619-623.
45. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26:1619-1625.
46. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
47. Schouwink JH, Codrington H, Sleeboom HP, et al. Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy. Eur J Cancer. 2008;44:819-829.
48. Tsuboi M, Ezaki K, Tobinai K, et al. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: Results of a multicenter, phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol. 2009;39:163-168.
49. Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: An exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer. 2009;9:311.
50. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colonystimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393-2400.
51. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia. 2007;21:627-632.
52. Volgger B, Petru E, Angleitner-Boubenizek L, et al. Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies: A randomised Austrian AGO trial. Anticancer Res. 2008;28:3977-3984.
53. National Kidney Foundation. KDOQI guidelines and commentaries. http://www.kidney.org/professionals/kdoqi/guidelines-commentaries.cfm
54. Centocor Ortho Biotech. Procrit (epoetin alfa). http://www. centocororthobiotech.com/cobi/oncology-procrit.html
55. Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006;107:1909-1917.
56. Crawford J, Robert F, Perry MC, et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007;2:210-220. (Pubitemid 47181326)
57. US Food and Drug Administration. Medication guide: Aranesp. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf
58. US Food and Drug Administration. Medication guide: Procrit. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088988.pdf
59. US Food and Drug Administration. Information on erythropoiesis- stimulating agents (ESA) epoetin alfa (marketed as Procrit, Epogen) darbepoetin alfa (marketed as Aranesp). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm
60. US Food and Drug Administration. Procrit label; Epogen label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/103234s5199lbl.pdf
61. US Food and Drug Administration. Aranesp label. http://www.accessdata. fda.gov/drugsatfda-docs/label/2010/103951s5197lbl.pdf
62. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. Am Soc Clin Oncol Ed Book. 2005;748-757.
63. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558-2560. (Pubitemid 44903859)
64. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: A meta-analysis. Ann Hematol. 2008;87:527-536.
65. Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009;115:706-715.
66. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol. 1998;103:1070-1074.
67. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood. 2004;104:321-327.
68. Danish Head and Neck Cancer Group. Study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. http://www.dahanca.dk/get-media-file.php?mediaid=125
69. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040-1050.
70. American Cancer Society. Cancer Facts and Figures for African Americans 2005-2006. Atlanta, GA, American Cancer Society, 2005
71. US Cancer Statistics Working Group. United States cancer statistics: 1999-2006 cancer incidence and mortality data. http://apps.nccd.cdc.gov/uscs/
72. Mead H, Cartwright-Smith L, Jones K, et al. Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
73. Ries LAG, Eisner MP, Kossary CL, et al. SEER cancer statistics review 1973-1997. http://seer.cancer.gov/csr/1975-2003/results-merged/topic-race- ethnicity.pdf
74. Smedley BD, Stith AY, Neson AR. Confronting Racial and Ethnic Disparities in Health Care. Washington, DC, National Academies Press, 2003
75. Hershman DL, Buono DL, Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst. 2009;101:1633-1641.
76. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol. 2009;27:3868-3874.